Trial Profile
A Phase Ia/Ib, Open-Label, Dose-Escalation, and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination With Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nofazinlimab (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Liver cancer; Malignant melanoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors CStone Pharmaceuticals
- 15 Dec 2022 Status changed from active, no longer recruiting to completed.
- 09 Aug 2022 Planned End Date changed from 1 Jan 2022 to 7 Jun 2023.
- 09 Aug 2022 Planned primary completion date changed from 31 Dec 2021 to 7 Jun 2023.